Cited in:


This article has been cited by:

  1. 1
    H.H. Loong, E. Winquist, J. Waldron, E.X. Chen, J. Kim, D. Palma, N. Read, A.R.A. Razak, I. Diaz-Padilla, K. Chan, A. Bayley, M. Hossain, L. Wang, S. Chin, L.L. Siu, A. Hope, Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx, European Journal of Cancer, 2014,


  2. 2
    M. G. Fury, E. J. Sherman, S. S. Rao, S. Wolden, S. Smith-Marrone, B. Mueller, K. K. Ng, P. R. Dutta, D. Y. Gelblum, J. L. Lee, R. Shen, S. Kurz, N. Katabi, S. Haque, N. Y. Lee, D. G. Pfister, Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC), Annals of Oncology, 2014, 25, 3, 689


  3. 3
    Sebastian Strieth, Christoph Dunau, Uwe Michaelis, Lorenz Jäger, Donata Gellrich, Barbara Wollenberg, Marc Dellian, Phase I/II clinical study on safety and antivascular effects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer, Head & Neck, 2014, 36, 7